229 related articles for article (PubMed ID: 37029424)
1. Dose escalation in oropharyngeal cancer: a comparison of simultaneous integrated boost and brachytherapy boost.
Embring A; Onjukka E; Mercke C; Lax I; Berglund A; Friesland S
Radiat Oncol; 2023 Apr; 18(1):65. PubMed ID: 37029424
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
3. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
4. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach.
Leclerc M; Maingon P; Hamoir M; Dalban C; Calais G; Nuyts S; Serre A; Grégoire V
Radiother Oncol; 2013 Mar; 106(3):333-40. PubMed ID: 23541643
[TBL] [Abstract][Full Text] [Related]
5. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of dose-escalated stereotactic radiosurgery (SRS) boost for unfavorable locally advanced oropharyngeal cancer.
Vempati P; Halthore AN; Teckie S; Rana Z; Gogineni E; Antone J; Zhang H; Marrero M; Beadle K; Frank DK; Aziz M; Paul D; Ghaly M
Radiat Oncol; 2020 Dec; 15(1):278. PubMed ID: 33308265
[TBL] [Abstract][Full Text] [Related]
7. Dose Escalation of Oropharyngeal Cancer: Long-Time Follow-Up and Side Effects.
Embring A; Onjukka E; Mercke C; Lax I; Berglund A; Friesland S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174046
[TBL] [Abstract][Full Text] [Related]
8. Institutional experience of interstitial brachytherapy for head and neck cancer with a comparison of high- and low dose rate practice.
Mohanti BK; Sahai P; Thakar A; Sikka K; Bhasker S; Sharma A; Sharma S; Bahadur S
Asian Pac J Cancer Prev; 2014; 15(2):813-8. PubMed ID: 24568501
[TBL] [Abstract][Full Text] [Related]
9. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.
Cvek J; Kubes J; Skacelikova E; Otahal B; Kominek P; Halamka M; Feltl D
Strahlenther Onkol; 2012 Aug; 188(8):666-70. PubMed ID: 22648405
[TBL] [Abstract][Full Text] [Related]
10. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol.
Pigorsch SU; Wilkens JJ; Kampfer S; Kehl V; Hapfelmeier A; Schläger C; Bier H; Schwaiger M; Combs SE
Radiat Oncol; 2017 Mar; 12(1):45. PubMed ID: 28249612
[TBL] [Abstract][Full Text] [Related]
11. Clinical research of the value of high-risk CTV setting on intensity-modulated radiotherapy for stage IIB-IVA cervical cancer.
Jiang Y; Wang J; Jiang P; Wang X; Zhang L; Zhang Y
BMC Cancer; 2023 May; 23(1):481. PubMed ID: 37245053
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous parametrial dose escalation in women with advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life.
Akbaba S; Oelmann-Avendano JT; Bostel T; Rief H; Nicolay NH; Debus J; Lindel K; Foerster R
Radiol Oncol; 2018 Sep; 52(3):320-328. PubMed ID: 30210042
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
Gerard JP; Barbet N; Schiappa R; Magné N; Martel I; Mineur L; Deberne M; Zilli T; Dhadda A; Myint AS;
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):356-367. PubMed ID: 36801007
[TBL] [Abstract][Full Text] [Related]
14. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I Study.
Sakanaka K; Ishida Y; Fujii K; Ishihara Y; Nakamura M; Hiraoka M; Mizowaki T
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):191-201. PubMed ID: 32768158
[TBL] [Abstract][Full Text] [Related]
15. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
[TBL] [Abstract][Full Text] [Related]
16. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial.
Welsh JW; Seyedin SN; Allen PK; Hofstetter WL; Ajani JA; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Nguyen QN; Minsky BD; Erasmus JJ; Lee JH; Bhutani M; Komaki RU
J Thorac Oncol; 2017 Feb; 12(2):375-382. PubMed ID: 27794500
[TBL] [Abstract][Full Text] [Related]
17. Adaptive dose escalated radiotherapy in oropharyngeal cancers: a treatment planning feasibility study.
Grocutt L; Paterson C; Valentine RM
Radiat Oncol; 2022 Feb; 17(1):24. PubMed ID: 35123516
[TBL] [Abstract][Full Text] [Related]
18. FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes.
Mapelli P; Broggi S; Incerti E; Alongi P; Kirienko M; Fiorino C; Dell Oca I; Fallanca F; Vanoli EG; Di Muzio NG; Gianolli L; Picchio M
Curr Radiopharm; 2017 Aug; 10(2):102-110. PubMed ID: 28412923
[TBL] [Abstract][Full Text] [Related]
19. Interstitial brachytherapy as boost for locally advanced T4 head and neck cancer.
Do L; Puthawala A; Syed N
Brachytherapy; 2009; 8(4):385-91. PubMed ID: 19733128
[TBL] [Abstract][Full Text] [Related]
20. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
